Mounting evidence from recent studies has demonstrated the clinical efficacy of HDAC inhibitors across various neurological disorders, including Parkinson’s disease and Alzheimer’s disease, among others (Zhang et al., 2024). Here, HDAC9 is linked to nervous system disorder.